Skip to main content

Advertisement

SpringerLink
Log in

Association of Plasma β-Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Decreased β-amyloid (Aβ) clearance from the brain has been suggested to contribute to cerebral Aβ accumulation in Alzheimer’s disease. Based on the idea of a dynamic Aβ equilibrium in different body compartments, plasma Aβ levels have been investigated as biomarker candidates for preclinical Alzheimer’s pathology, yet with inconsistent results. Since the kidneys are involved in Aβ elimination from the blood, we evaluated how chronic kidney disease (CKD) affects the association between plasma Aβ and cognitive deficits and cognitive decline. In 28 CKD patients, stages 3–5D, and 26 control subjects with comparable vascular risk profile from the New Tools for the Prevention of Cardiovascular Disease in Chronic Kidney Disease (NTCVD) cohort, plasma total Aβ was determined with a highly sensitive electrochemiluminescence immunoassay. Cognition was evaluated using a comprehensive battery of ten neuropsychological tests at baseline and 2-year follow-up. Subjects with high plasma Aβ level (above median) demonstrated a significantly worse baseline cognitive performance than subjects exhibiting low Aβ level (summary score of global cognitive performance at baseline z = −0.46 ± 0.76 vs z = −0.08 ± 0.57, p = 0.045). Cognitive performance moderately decreased over the 2-year follow-up in subjects with high plasma Aβ level (Δz = −0.13 ± 0.51), but increased in subjects with low plasma Aβ level (Δz = 0.16 ± 0.41, p = 0.023). In linear regression analyses, baseline plasma Aβ was significantly associated with cognitive decline both in unadjusted analyses (β = −0.28, 95% CI = −0.55 to −0.01) and analyses adjusted for age (β = −0.27, 95% CI = −0.54 to −0.01). Our results suggest the utility of plasma Aβ level in predicting cognitive decline in patients suffering from CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abdullah L, Paris D, Luis C, Quadros A, Parrish J, Valdes L, Keegan AP, Mathura V et al (2007) The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett 428(2–3):53–58. doi:10.1016/j.neulet.2007.09.058

    Article  CAS  PubMed  Google Scholar 

  2. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR (2002) Serum creatinine levels correlate with plasma amyloid Beta protein. Alzheimer Dis Assoc Disord 16(3):187–190

    Article  CAS  PubMed  Google Scholar 

  3. Aschenbrenner S, Tucha O, Lange KW (2000) Regensburger Wortflüssigkeits-Test (RWT). Hogrefe, Göttingen

    Google Scholar 

  4. Bäumler G (1985) Farb-Wort-Interferenztest (FWIT) nach J.R. Stroop. Hogrefe, Göttingen

  5. Cammarata S, Borghi R, Giliberto L, Pardini M, Pollero V, Novello C, Fornaro M, Vitali A et al (2009) Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. J Alzheimer’s Dis: JAD 18(2):267–271. doi:10.3233/jad-2009-1144

    Article  CAS  PubMed  Google Scholar 

  6. Chiu MJ, Yang SY, Horng HE, Yang CC, Chen TF, Chieh JJ, Chen HH, Chen TC et al (2013) Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chem Neurosci 4(12):1530–1536. doi:10.1021/cn400129p

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX, Schupf N, Mayeux RP (2010) Plasma ss-amyloid and cognitive decline. Arch Neurol 67(12):1485–1490. doi:10.1001/archneurol.2010.189

    Article  PubMed  PubMed Central  Google Scholar 

  8. Fullwood NJ, Hayashi Y, Allsop D (2006) Plasma amyloid-beta concentrations in Alzheimer’s disease: an alternative hypothesis. Lancet Neurol 5(12):1000–1001. doi:10.1016/s1474-4422(06)70611-1author reply 1002-1003

    Article  PubMed  Google Scholar 

  9. Gronewold J, Klafki HW, Baldelli E, Kaltwasser B, Seidel UK, Todica O, Volsek M, Haussmann U et al (2015) Factors responsible for plasma beta-amyloid accumulation in chronic kidney disease. Mol Neurobiol. doi:10.1007/s12035-015-9218-y

    PubMed  Google Scholar 

  10. Hansson O, Stomrud E, Vanmechelen E, Ostling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I (2012) Evaluation of plasma Abeta as predictor of Alzheimer’s disease in older individuals without dementia: a population-based study. J Alzheimer’s Dis: JAD 28(1):231–238. doi:10.3233/jad-2011-111418

    CAS  PubMed  Google Scholar 

  11. Härting C, Markowitsch HJ, Neufeld U, Calabrese P, Deisinger K, Kessler J (2000) Wechsler Memory Scale—revised edition, German edn. Huber, Bern

    Google Scholar 

  12. Herrmann-Lingen C, Buss U, Snaith RP (2005) Hospital Anxiety and Depression Scale - Deutsche Version (HADS-D). Hans Huber, Bern

    Google Scholar 

  13. Jack CR Jr, Holtzman DM (2013) Biomarker modeling of Alzheimer’s disease. Neuron 80(6):1347–1358. doi:10.1016/j.neuron.2013.12.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F (2012) Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 69(7):824–831. doi:10.1001/archneurol.2011.1841

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR et al (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268(3):750–756. doi:10.1006/bbrc.2000.2222

    Article  CAS  PubMed  Google Scholar 

  16. Liu YH, Xiang Y, Wang YR, Jiao SS, Wang QH, Bu XL, Zhu C, Yao XQ et al (2014) Association between serum amyloid-beta and renal functions: implications for roles of kidney in amyloid-beta clearance. Mol Neurobiol. doi:10.1007/s12035-014-8854-y

    Google Scholar 

  17. Liu YH, Wang YR, Xiang Y, Zhou HD, Giunta B, Manucat-Tan NB, Tan J, Zhou XF et al (2015) Clearance of amyloid-beta in Alzheimer’s disease: shifting the action site from center to periphery. Mol Neurobiol 51(1):1–7. doi:10.1007/s12035-014-8694-9

    Article  PubMed  Google Scholar 

  18. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R et al (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70(19):1664–1671. doi:10.1212/01.wnl.0000306696.82017.66

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science (New York, NY) 330(6012):1774. doi:10.1126/science.1197623

    Article  CAS  Google Scholar 

  20. Nettiksimmons J, Ayonayon H, Harris T, Phillips C, Rosano C, Satterfield S, Yaffe K (2015) Development and validation of risk index for cognitive decline using blood-derived markers. Neurology 84(7):696–702. doi:10.1212/wnl.0000000000001263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Okereke OI, Xia W, Selkoe DJ, Grodstein F (2009) Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 66(10):1247–1253. doi:10.1001/archneurol.2009.207

    Article  PubMed  PubMed Central  Google Scholar 

  22. Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. doi:10.1016/s1474-4422(16)00070-3

    Google Scholar 

  23. Panza F, Solfrizzi V, Imbimbo BP, Logroscino G (2014) Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return? Expert Opin Biol Ther 14(10):1465–1476. doi:10.1517/14712598.2014.935332

    Article  CAS  PubMed  Google Scholar 

  24. Pilotto A, Panza F, Sancarlo D, Paroni G, Maggi S, Ferrucci L (2012) Usefulness of the multidimensional prognostic index (MPI) in the management of older patients with chronic kidney disease. J Nephrol 25(Suppl 19):S79–S84. doi:10.5301/jn.5000162

    Article  PubMed  Google Scholar 

  25. Poljak A, Crawford JD, Smythe GA, Brodaty H, Slavin MJ, Kochan NA, Trollor JN, Wen W, et al (2016) The relationship between plasma Abeta levels, cognitive function and brain volumetrics: Sydney Memory and Ageing Study. Curr Alzheimer Res 13(3):243–255.

  26. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD (2005) Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatr: Off J Am Assoc Geriatr Psychiatr 13(10):914–917. doi:10.1176/appi.ajgp.13.10.914

    Google Scholar 

  27. Reitan RM (1992) Trail making test. Reitan Neuropsychology Laboratory, Tucson, AZ

    Google Scholar 

  28. Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC et al (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimer’s & Dementia : J Alzheimer’s Assoc 5(1):18–29. doi:10.1016/j.jalz.2008.10.004

    Article  CAS  Google Scholar 

  29. Russ M (2002) Rey complex figure test. Anleitung für die Anwendung im Frankfurter Neuropsychologischen Testprofil (FNTP). http://www.fntp.de/mediapool/80/807841/data/CFT_Scoring.pdf. Accessed 5 Sept 2012

  30. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, Steppan S, Volsek M et al (2012) Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 35(1):31–39. doi:10.1159/000334742

    Article  CAS  PubMed  Google Scholar 

  31. Seidel UK, Gronewold J, Volsek M, Todica O, Kribben A, Bruck H, Hermann DM (2014) The prevalence, severity, and association with HbA1c and fibrinogen of cognitive impairment in chronic kidney disease. Kidney Int 85(3):693–702. doi:10.1038/ki.2013.366

    Article  CAS  PubMed  Google Scholar 

  32. Seppala TT, Herukka SK, Hanninen T, Tervo S, Hallikainen M, Soininen H, Pirttila T (2010) Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81(10):1123–1127. doi:10.1136/jnnp.2010.205757

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS (2011) Meta-analysis of plasma amyloid-beta levels in Alzheimer’s disease. J Alzheimer’s Dis: JAD 26(2):365–375. doi:10.3233/jad-2011-101977

    CAS  PubMed  Google Scholar 

  34. Takata M, Nakashima M, Takehara T, Baba H, Machida K, Akitake Y, Ono K, Hosokawa M et al (2008) Detection of amyloid beta protein in the urine of Alzheimer’s disease patients and healthy individuals. Neurosci Lett 435(2):126–130. doi:10.1016/j.neulet.2008.02.019

    Article  CAS  PubMed  Google Scholar 

  35. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H et al (2015) Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 11(8):457–470. doi:10.1038/nrneurol.2015.119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L et al (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305(3):261–266. doi:10.1001/jama.2010.1995

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank Gisela Behrendt for the administrative and technical support.

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital Essen, Hufelandstraße 55, 45122, Essen, Germany

    Janine Gronewold, Olga Todica, Ulla K. Seidel, Britta Kaltwasser & Dirk M. Hermann

  2. Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, von-Siebold-Straße 5, 37075, Goettingen, Germany

    Hans-Wolfgang Klafki & Jens Wiltfang

  3. Department of Nephrology, University Hospital Essen, Hufelandstraße 55, 45122, Essen, Germany

    Andreas Kribben & Heike Bruck

Authors
  1. Janine Gronewold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olga Todica
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans-Wolfgang Klafki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ulla K. Seidel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Britta Kaltwasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jens Wiltfang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andreas Kribben
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Heike Bruck
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dirk M. Hermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk M. Hermann.

Ethics declarations

Funding

The study was supported by the Federal Ministry of Education and Research (BMBF/NGFN 01GR0808), which was not involved in the study design, in the collection, analysis, and interpretation of data; in writing the report; and in the decision to submit the article for publication.

Conflict of Interest

The authors declare that they have no conflict of interest.

Electronic Supplementary Material

ESM 1

(DOCX 28 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gronewold, J., Todica, O., Klafki, HW. et al. Association of Plasma β-Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease. Mol Neurobiol 54, 7194–7203 (2017). https://doi.org/10.1007/s12035-016-0243-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-016-0243-2

Keywords

Search

Navigation